SCHEMBL24660470

SCHEMBL24660470

COc1cc(-c2noc([C@H](C)NC(=O)OC(C)(C)C)n2)ccn1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KCNT1 Q5JUK3 11/20 0.61
▸ PPARD Q03181 3/20 0.47
▸ PPARA Q07869 3/20 0.47
▸ KCNQ1 P51787 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ CACNA1C Q13936 1/20 0.47
▸ SCN5A Q14524 1/20 0.47
▸ KCNMB1 Q16558 1/20 0.47
▸ KCNT2 Q6UVM3 1/20 0.47
▸ AAK1 Q2M2I8 1/20 0.46
▸ TP53 P04637 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ S1PR1 P21453 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.43
▸ ACACB O00763 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24660613 1.00 KCNT1 (0.61) KCNT1PPARDPPARAKCNQ1KCNH2
SCHEMBL24660775 1.00 KCNT1 (0.61) KCNT1PPARDPPARAKCNQ1KCNH2
SCHEMBL34466485 0.93 KCNT1 (0.54) KCNT1PPARDPPARAKCNQ1KCNH2
SCHEMBL25601543 0.91 KCNT1 (0.51) KCNT1PPARDPPARAKCNQ1KCNH2
SCHEMBL24660827 0.90 ACACB (0.51) KCNT1PPARDPPARAKCNQ1KCNH2
SCHEMBL24660174 0.87 KCNT1 (0.48) KCNT1PPARDPPARAKCNQ1KCNH2
SCHEMBL22637519 0.87 KCNT1 (0.59) KCNT1PPARDPPARAKCNQ1KCNH2
SCHEMBL24660575 0.87 KCNT1 (0.59) KCNT1PPARDPPARAKCNQ1KCNH2
SCHEMBL24660721 0.87 KCNT1 (0.59) KCNT1PPARDPPARAKCNQ1KCNH2
SCHEMBL24660475 0.87 KCNT1 (0.49) KCNT1PPARDPPARAKCNQ1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109692-A1 KCNT1 INHIBITORS AND METHODS OF USE UCB Biopharma SRL (BE) 2026-04-23 — — US disclosed
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2022-08-18 — — US disclosed
EP-3962481-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2022-03-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 KCNT1 1/4885PPARD 4482/4885PPARA 4478/4885
US-20260109692-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNJ2, KCNT2 KCNT1 1/4885PPARD 3460/4885PPARA 3089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback